… From the 705 774 eligible patients, we matched 83 022 pairs … matched cohort had a mean
(SD) age of 60.1 (11.6) years; … HbA 1C was 0.30% in the rosuvastatin group and 0.22% in the …

… decrease with rosuvastatin 10 mg in LDL-C (–0.67 mmol/L vs –0.54 mmol/L) and TC (–… -C
decrease.47, 48 In addition, age at PCI was a significant factor in LDL-C reduction; however, …

… to 1.04) for atherosclerotic CVD and 0.98 (0.91 to 1.05) for all … aged 85 and older were 0.93
(0.82 to 1.06) and 0.97 (0.90 to 1.05… of statin use in 75-84 year olds was 0.76 (0.65 to 0.89) for …

… % for rosuvastatin. At some point during FY … , resulting in insulin resistance; expression on
microRNA, resulting in impairment on insulin secretion and induction of β-cell dysfunction [48]. …

… This retrospective, cohort study was conducted using … within 28 days of their index stroke
were propensity score-matched with those who did not. Patients were followed up for up to 2 …

… The rosuvastatin formulations did not exhibit clinically significant non-lipid effects with good
safety profiles. Our study provides comprehensive data regarding 2 rosuvastatin formulations …

… a retrospective cohort study to evaluate long-term preoperative intake of atorvastatin and
rosuvastatin … scheduled CABG [48], other studies demonstrated that it usually takes 14 days or …

… Of the 755 final participants, 48 patients experienced primary … rosuvastatin groups were 0.956
(0.456–2.005), 1.347 (0.354–… The present study is a retrospective national cohort study that …

… The objective of this study was to compare the efficacy and safety of combination therapy
with ezetimibe and rosuvastatin versus those of rosuvastatin monotherapy in patients with …

… year of treatment (1-year adjusted hazard ratio 1.19; 95% confidence interval (CI) 1.15–1.23).
The … was even higher (1-year adjusted hazard ratio 1.38; 95% CI 1.30–1.69). High-intensity …